On June 11, 2025, AIM ImmunoTech Inc. confirmed it has regained compliance with NYSE American standards and will reinstate trading of its common stock on June 17, 2025, after previously executing a 1-for-100 reverse stock split authorized by shareholders on April 30, 2025. The units will trade under the ticker 'AIM'.